KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Assets: 2009-2024

Historic Current Assets for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $2.6 billion.

  • Ionis Pharmaceuticals' Current Assets fell 7.18% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 7.18%. This contributed to the annual value of $2.6 billion for FY2024, which is 0.82% down from last year.
  • Ionis Pharmaceuticals' Current Assets amounted to $2.6 billion in FY2024, which was down 0.82% from $2.6 billion recorded in FY2023.
  • In the past 5 years, Ionis Pharmaceuticals' Current Assets ranged from a high of $2.6 billion in FY2023 and a low of $2.1 billion during FY2020.
  • For the 3-year period, Ionis Pharmaceuticals' Current Assets averaged around $2.5 billion, with its median value being $2.6 billion (2024).
  • Per our database at Business Quant, Ionis Pharmaceuticals' Current Assets declined by 21.68% in 2020 and then increased by 19.94% in 2023.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Current Assets stood at $2.1 billion in 2020, then grew by 10.06% to $2.3 billion in 2021, then decreased by 6.07% to $2.2 billion in 2022, then climbed by 19.94% to $2.6 billion in 2023, then declined by 0.82% to $2.6 billion in 2024.